Answers are grounded in this paper and cite their sources.
Cases of the steroid-resistant nephrotic syndrome that are resistant to rituximab can be difficult to treat. In this report, ofatumumab, an anti-CD20 monoclonal antibody, showed some benefit in five young patients.
No takes yet. Share an insight, caveat, or question.
Biswanath Basu (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: